An association between Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta analysis.
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials / Nreu, Besmir; Dicembrini, Ilaria; Tinti, Federico; Mannucci, Edoardo; Monami, Matteo. - In: MINERVA ENDOCRINOLOGICA. - ISSN 0391-1977. - ELETTRONICO. - (2020), pp. 0-0. [10.23736/S0391-1977.20.03219-8]
Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials
Nreu, Besmir;Dicembrini, Ilaria;Mannucci, Edoardo;Monami, Matteo
2020
Abstract
An association between Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) and risk of pancreatitis and pancreatic cancer has been suggested. Since its first description, several new trials (including three cardiovascular outcome trials) have been published, substantially increasing the available data set. This suggests the need for an update of the previous meta analysis.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
